GlassScriptPhysician profile
Jesse H Eisenman
NPI 1770581720
$8,965.95
in general payments reported to CMS, 2019-2025
36 companies · $1,911 in 2025
The $1,911 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,342 · 2020: $393 · 2021: $954 · 2022: $1,615 · 2023: $1,410 · 2024: $1,341 · 2025: $1,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,662.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,212.95 | 2019-2025 | |
| Gilead Sciences, INC. | $1,142.92 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $943.89 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $831.13 | 2019-2025 | Stelara, Tremfya, Simponi |
| Phathom Pharmaceuticals, INC. | $410.25 | 2024-2025 | Voquezna |
| Celgene Corporation | $406.80 | 2021-2024 | Zeposia |
| Genzyme Corporation | $305.93 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $275.97 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $242.71 | 2024-2025 | Iqirvo |
| Ucb, INC. | $232.42 | 2019-2021 | |
| Redhill Biopharma INC. | $203.48 | 2021-2022 | |
| Pfizer INC. | $203.23 | 2019-2025 | |
| Vivus LLC | $162.88 | 2019-2025 | Pancreaze, Qsymia |
| Ardelyx, INC. | $141.29 | 2024-2025 | Ibsrela |
| Braintree Laboratories, INC. | $137.73 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $124.73 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $107.09 | 2019-2023 | Rebyota |
| Madrigal Pharmaceuticals | $101.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $96.23 | 2023-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.78 | 2019-2025 | Trulance, Xifaxan |
| Shire North American Group INC | $82.13 | 2019 | |
| Boston Scientific Corporation | $58.30 | 2022-2025 | Exalt Model D |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.14 | 2023 | Cyltezo |
| Cook Medical LLC | $55.29 | 2020 | |
| Novo Nordisk INC | $50.39 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $50.19 | 2022-2023 | Linzess |
| Medtronic, INC. | $49.24 | 2022-2023 | Interstim |
| Intuitive Surgical, INC. | $33.72 | 2020 | |
| Apollo Endosurgery US INC | $25.25 | 2022 | |
| Biocon Biologics INC | $24.52 | 2025 | Yesintek |
| Organon LLC | $20.20 | 2023-2024 | Hadlima |
| Tersera Therapeutics LLC | $18.34 | 2022 | |
| Amgen INC. | $17.84 | 2022 | |
| Daiichi Sankyo INC. | $17.25 | 2019 | |
| Olympus America INC. | $14.67 | 2023 | Single Use Grasping Forceps |
| Allergan, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Eisenman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.